These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21272643)

  • 1. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.
    Saint-Marcoux F; Guigonis V; Decramer S; Gandia P; Ranchin B; Parant F; Bessenay L; Libert F; Harambat J; Bouchet S; Broux F; Compagnon P; Marquet P
    Pharmacol Res; 2011 May; 63(5):423-31. PubMed ID: 21272643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome.
    Benz MR; Ehren R; Kleinert D; Müller C; Gellermann J; Fehrenbach H; Schmidt H; Weber LT
    Ther Drug Monit; 2019 Dec; 41(6):696-702. PubMed ID: 31425441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
    Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
    Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.
    Zhao W; Elie V; Baudouin V; Bensman A; André JL; Brochard K; Broux F; Cailliez M; Loirat C; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2010 Apr; 69(4):358-66. PubMed ID: 20406220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease.
    de Winter BC; Neumann I; van Hest RM; van Gelder T; Mathot RA
    Ther Drug Monit; 2009 Jun; 31(3):382-90. PubMed ID: 19363460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
    Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.
    Saint-Marcoux F; Royer B; Debord J; Larosa F; Legrand F; Deconinck E; Kantelip JP; Marquet P
    Clin Pharmacokinet; 2009; 48(10):667-75. PubMed ID: 19743888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring.
    Woillard JB; Bader-Meunier B; Salomon R; Ranchin B; Decramer S; Fischbach M; Berard E; Guigonis V; Harambat J; Dunand O; Tenenbaum J; Marquet P; Saint-Marcoux F
    Br J Clin Pharmacol; 2014 Oct; 78(4):867-76. PubMed ID: 24697955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients.
    Woillard JB; Saint-Marcoux F; Monchaud C; Youdarène R; Pouche L; Marquet P
    Pharmacol Res; 2015 Sep; 99():308-15. PubMed ID: 26192348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters.
    Sobiak J; Resztak M; Ostalska-Nowicka D; Zachwieja J; Gąsiorowska K; Piechanowska W; Chrzanowska M
    Eur J Pharm Sci; 2015 Sep; 77():189-96. PubMed ID: 26102431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
    Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
    Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm.
    Koloskoff K; Benito S; Chambon L; Dayan F; Marquet P; Jacqz-Aigrain E; Woillard JB
    Eur J Clin Pharmacol; 2024 Jan; 80(1):83-92. PubMed ID: 37897528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine.
    Hibino S; Nagai T; Yamakawa S; Ito H; Tanaka K; Uemura O
    Clin Exp Nephrol; 2017 Feb; 21(1):152-158. PubMed ID: 27105859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
    de Winter BC; Monchaud C; Prémaud A; Pison C; Kessler R; Reynaud-Gaubert M; Dromer C; Stern M; Guillemain R; Knoop C; Estenne M; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Jan; 51(1):29-39. PubMed ID: 22054177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine.
    Pawinski T; Kunicki PK; Sobieszczanska-Malek M; Gralak B; Szlaska I
    J Clin Pharm Ther; 2009 Feb; 34(1):89-101. PubMed ID: 19125907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.